Filing Flows › Industries › Industrials › Services-Testing Laboratories
Services-Testing Laboratories SIC 8734
3 companies filing with the SEC under SIC 8734. Median revenue growth +8% year on year in Q3 2026 (2 companies). The growth model expects the industry's combined revenue to grow +7% in Q3 2026. 1 customer or supplier links named in annual reports.
Money flow: where the industry's revenue goes
Drawn in the browser: an estimate of where the industry's revenue goes — what it buys from other industries, the pay that reaches households, taxes and profit — beside its filed cash flow, two tiers of suppliers and its capital spending by kind of asset.
Open the industry: growth distribution, money flow, network →
Who sells to whom
Customers and suppliers named in the companies' annual reports; the share is of the supplier's revenue.
- NEO → Medicare & Medicaid 13% of the supplier's revenue, $94.6M
Growth model
Industry revenue, the same companies year on year; 80% ranges. Fitted on SEC filings and tested out of sample (how).
| Quarter | Growth Y/Y | Revenue | 80% range |
|---|---|---|---|
| Q3 2026 | +6.7% | $1.0B | $1.0B – $1.1B |
| Q4 2026 | +6.9% | $1.0B | $1.0B – $1.1B |
| Q1 2027 | +7.0% | $1.0B | $985M – $1.0B |
| Q2 2027 | +7.0% | $1.1B | $1.1B – $1.1B |
Capital spending and supply chain →
Companies
| Company | Quarterly revenue | Y/Y | Stage |
|---|---|---|---|
| ULS UL Solutions | $823M | +5% | mature |
| NEO Neogenomics | $209M | +11% | transition |
| AIDX 20/20 Biolabs | $731K | — | reacceleration |
Growth from positive, comparable quarterly revenue as filed; industries are SEC Standard Industrial Classification codes. Data Nov 8, 2026.